Challenging the EAU 2009 Guidelines on Testis Cancer: The Risk-Adapted Management of Stage I Nonseminomatous Germ Cell Tumours: Surveillance Yields Equal Results With Less Toxicity

European Urology, Supplements

Volumn 9, Issue 3, 2010, Pages 459-461

  Brewster, Simon F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

NSGCT stage 1; Surveillance; Testis cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; KI 67 ANTIGEN; TUMOR MARKER;

ANXIETY DISORDER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; EMBRYONAL CARCINOMA; HAIR LOSS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE INFERTILITY; MEDLINE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; RISK MANAGEMENT; SALVAGE THERAPY; SECOND CANCER; SIDE EFFECT; TESTIS CANCER; TREATMENT OUTCOME; WEIGHT; YOLK SAC TUMOR;

EID: 77950521453     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.03.001     Document Type: Review

References (15)

1. Colls B.M., Harvey V.J., Skelton L., et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 83 (1999) 76-82
2. Vergouwe Y., Steyerberg E.W., Eijkemans M.J., Albers P., and Habbema J.D. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21 (2003) 4092-4099
3. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Testis_Cancer.pdf. Updated 2009.
4. Albers P., Siener R., Kleisch S., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ-cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 21 (2003) 1505-1512
5. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ-cell tumours of the testis. A Medical Research Council report. J Clin Oncol 14 (1996) 1106-1113
6. Krege S., Beyer J., Souchon R., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53 (2008) 497-513
7. Tandstad T., Dahl O., Cohn-Cedermark G., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27 (2009) 2122-2128
8. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
9. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
10. Fosså S.D., Aass N., Winderen M., Börmer O.P., and Olsen D.R. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13 (2002) 222-228
11. Sagstuen H., Aass N., Fosså S.D., et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23 (2005) 4980-4990
12. Strumberg D., Brügge S., Korn M.W., et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13 (2002) 229-236
13. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (2007) 4370-4378
14. Zuniga A., Kakiashvili D., and Jewett M.A.S. Surveillance in stage 1 nonseminomatous germ cell tumours of the testis. BJU Int 104 (2009) 1351-1356
15. Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. In press. doi:10.1093/annonc/mdp473.